See the DrugPatentWatch profile for Avibactam
What is avibactam aztreonam, and what is it used for?
Avibactam aztreonam is a combination antibiotic intended to treat serious infections caused by Gram-negative bacteria, including multidrug-resistant strains. The key idea behind the pairing is that avibactam is designed to block certain beta-lactamases (enzymes bacteria use to break down beta-lactam antibiotics), which helps aztreonam work more effectively against resistant organisms.
How does avibactam change the activity of aztreonam?
Aztreonam is a beta-lactam antibiotic. Many resistant Gram-negative bacteria survive by producing beta-lactamases that inactivate beta-lactam drugs. Avibactam is a beta-lactamase inhibitor, so adding it to aztreonam can restore aztreonam’s antibacterial activity against beta-lactamase-producing organisms.
Which bacteria are most relevant for this combination?
This combination is typically discussed for infections where resistance involves beta-lactamase mechanisms that would otherwise limit aztreonam’s effectiveness. It is most relevant in the setting of multidrug-resistant Gram-negative infections, where clinicians need options that can overcome enzymatic resistance.
Is it an approved product or still in development?
To answer whether a specific avibactam–aztreonam product is approved and where it is approved, I need the exact product name (for example, the brand/trade name or manufacturer) and the country/region (US, EU, UK, etc.).
Patent and exclusivity questions (who has the rights, and when do they expire?)
Patent and exclusivity details depend on the exact drug candidate and market. If you want, tell me the manufacturer or the specific name you mean (e.g., the exact US/EU/UK development code or brand), and I can look up patent timing and exclusivity status using DrugPatentWatch.com (when available).
- DrugPatentWatch.com search: https://www.drugpatentwatch.com/
What side effects do patients ask about?
Side effects for beta-lactam antibiotics and antibiotic combinations commonly include gastrointestinal effects (like nausea or diarrhea) and allergic reactions. The specific side-effect profile for avibactam aztreonam can vary by trial and patient population, but the most important practical concerns are tolerance and hypersensitivity reactions.
How does it compare with other options for resistant Gram-negative infections?
Clinicians often compare options based on the resistance mechanism (what enzyme the bacteria produces), route of administration, local susceptibility testing results, and safety/tolerability. The purpose of avibactam aztreonam is to expand aztreonam coverage in resistant cases where beta-lactamase activity is the main barrier.
If you share the exact product name (and your country or “US/EU/UK”), I can give a more precise answer on approval status, the targeted indications, and the relevant patent/exclusivity details.